Autoimmune Idiopathic Inflammatory Myopathies: Pharmacological Differences and Similarities by Type of Myositis and by Sociodemographic Variables

Table 2

Comparison of some sociodemographic and pharmacological variables between women and men diagnosed with autoimmune idiopathic inflammatory myopathies in Colombia.

Variables	Women		Men
		%		%
Age, median (IQR)	53.0 (41.0-64.0)		53.0 (41.0-64.0)		0.054
Type of inflammatory myopathy	—	—	—	—	—
Overlap myositis	173	36.3	38	19.5	<0.001
Polymyositis	118	24.8	80	41.0	<0.001
Other dermatomyositis	96	20.2	49	25.1	0.156
Dermatopolymyositis	86	18.1	27	13.8	0.185
Juvenile dermatomyositis	3	0.6	1	0.5	1.000
Comorbidities	397	83.4	138	70.8	<0.001
Arterial hypertension	187	39.3	62	31.8	0.068
Diabetes mellitus	104	21.8	35	17.9	0.258
Hypothyroidism	96	20.2	28	14.4	0.078
Rheumatoid arthritis	97	20.4	22	11.3	0.005
Chronic pain	61	12.8	16	8.2	0.089
Infections	119	25.0	38	19.5	0.126
Pharmacotherapy	441	92.6	173	88.7	0.097
Systemic glucocorticoids	380	79.8	147	75.4	0.203
Prednisolone	305	64.1	109	55.9	0.048
Prednisone	117	24.6	32	16.4	0.021
Dexamethasone	90	18.9	29	14.9	0.214
Methylprednisolone	43	9.0	9	4.6	0.052
Pulses	9	1.9	1	0.5	0.295
Deflazacort	35	7.4	12	6.2	0.581
Betamethasone	22	4.6	8	4.1	0.768
Hydrocortisone	9	1.9	1	0.5	0.295
Conventional DMARDs	366	76.9	131	67.2	0.009
Azathioprine	238	50.0	89	45.6	0.305
Methotrexate	181	38.0	61	31.3	0.099
Chloroquine	82	17.2	23	11.8	0.079
Hydroxychloroquine	27	5.7	5	2.6	0.086
Sulfasalazine	5	1.1	1	0.5	0.678
Leflunomide	3	0.6	2	1.0	0.631
Immunosuppressants	43	9.0	18	9.2	0.936
Mycophenolate	17	3.6	7	3.6	0.991
Cyclosporine	16	3.4	5	2.6	0.590
Cyclophosphamide	15	3.2	6	3.1	0.960
Human immunoglobulin	4	0.8	1	0.5	1.000
Biological DMARDs	19	4.0	6	3.1	0.570
Rituximab	17	3.6	4	2.1	0.464
Others ()^	2	0.4	2	1.0	0.584
Comedications	—	—	—	—	—
Analgesics	328	68.9	121	62.1	0.087
Antiulcer	312	65.5	101	51.8	0.001
Antihypertensives and diuretics	216	45.4	72	36.9	0.045
Nonsteroidal anti-inflammatory drugs	204	42.9	79	40.5	0.577
Antihistamines	189	39.7	53	27.2	0.002

IQR: interquartile range; DMARD: disease-modifying antirheumatic drugs. Mann–Whitney test. Fisher’s exact test. ^Others: adalimumab, abatacept, belimumab, and certolizumab.